Our findings that the CypA inhibitors C9 and CsA inhibit EGFR activity and the EGFR inhibitor afatinib inhibits CypA/CD147 expression suggest that there is close crosstalk between the CypA/CD147 and EGFR pathways in regulating the stem-like properties of NSCLC. This evidence concerns the gene EGFR and non-small cell lung carcinoma.